13th Annual Global Embolization Symposium & Technologies
Purpose : The objective of this study was to investigate the plasma pharmacokinetic profiles, intratumoral concentration and tissue distribution of arsenic trioxide (ATO) after administration via drug-eluting beads (DEB)- transcatheter arterial chemoembolization (TACE) in a rabbit model with liver tumor.
Material and Methods : Sixty-four rabbit models with VX2 liver tumor were established and randomly assigned to 4 groups averagely. CSM-ATO group received DEB-TACE treatment of ATO-loaded CSM (0.5 mg/kg of ATO); cTACE-ATO group received conventional TACE treatment of ATO mixed with lipiodol (0.5 mg/kg of ATO); CalliSpheres Microspheres (CSM)-NC（CSM-NC）group received chemoembolization with black CSM; cTACE-NC group received hepatic intraarterial infusion of normal saline mixed with lipiodol. Plasma pharmacokinetics, intratumoral concentration, tissue distribution, liver and kidney toxicity of ATO post treatment were evaluated and compared.
Results : CSM-ATO group exhibited lower plasma ATO concentrations at 10 minutes and 20 minutes whereas higher concentration at 3 days post treatment compared with cTACE-ATO group. Meanwhile, intratumoral ATO concentrations were higher in CSM-ATO group compared with cTACE-ATO group at 3, 7 and 14 days post treatment. In normal liver tissue, heart and muscle tissues, ATO concentrations between CSM-ATO group and cTACE group were similar at each time point; in kidney and lung tissues, ATO concentrations were also similar at 3, 7 and 14 days post treatment. Besides, liver or kidney function indexes were of no difference at each time point between CSM-ATO and cTACE-ATO groups.
Conclusions : Administration of ATO via DEB-TACE provides better plasma pharmacokinetic profiles and higher intratumoral concentration without increasing liver and kidney toxicity compared with cTACE.